MRM Proteomics is a technology provider and contract research organization/research partner delivering advanced proteomics technologies in the form of research services, kits, and clinical assays for applications in the pharmaceutical & biotechnology industries.
We offer the widest variety of high quality proteomics services and we specialize in development of custom-tailored technologies for our clients’ specific research needs.
We are also involved in the development of several clinical proteomics assays such as those for patient stratification for targeted cancer treatments. These projects, with large pharmaceutical and clinical research partners, commonly use our patented iMALDI technology, which is compatible with clinically available instrumentation and automation.
MRM Proteomics has launched a line of MS kits for do-it-yourself targeted quantitation. The PeptiQuant Plus line includes kits for human plasma and mouse plasma, as well as dedicated products to assist with quality control of MS-based proteomics. They have been optimized for use on a wide variety of mass spectrometry platforms.
All of our assays are developed and characterized according to rigorous guidelines established by the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). This feature is unique to MRM Proteomics’ assays.
In addition to our protein quantitation assays, we provide top of the line high resolution structural characterization of proteins and biosimilars by top-down and bottom-up HDX.

MRM Proteomics Inc. was established in 2010 as a spin-out company to commercialize the cutting-edge proteomics technologies, tools and know-how developed at the University of Victoria-Genome BC Proteomics Centre.